Daily Archives: February 1, 2022
WHO Recommendations: Reducing the risk of cognitive decline and dementia.
1 Feb, 2022 | 09:50h | UTCReducing the Risk of Cognitive Decline and Dementia: WHO Recommendations – Frontiers in Neurology
Related:
New WHO toolkit promotes inclusion of people with dementia in society.
Dementia: number of people affected to triple in next 30 years – World Health Organization
SCAI SHOCK Cardiogenic Shock Classification Expert Consensus Update.
1 Feb, 2022 | 09:53h | UTCNews Release: SCAI releases updated expert consensus to SCAI SHOCK classification – Society for Cardiovascular Angiography and Interventions
Commentaries:
SCAI SHOCK: Update Refines Cardiogenic Shock Classification – TCTMD
SCAI Releases Updated Expert Consensus to SCAI SHOCK Classification – American College of Cardiology
Commentaries on Twitter
.@SCAI SHOCK stage is an indication of shock severity & comprises one component of mortality risk prediction in pts w/ CS, along w/ etiology/phenotype & other risk modifiers; a 3-axis model of risk stratification in CS has been proposed. Learn more: https://t.co/tnh2JFhHzN #JACC pic.twitter.com/yK2ye9wcd0
— JACC Journals (@JACCJournals) January 31, 2022
SCAI SHOCK Stage Classification Expert Consensus Update released today in the inaugural issue of @MyJSCAI and also in @JACCJournals. Thank you to endorsing societies @ACCinTouch @american_heart @ACEPNow @escardio @ACVCPresident @ISHLT @SCCM @STS_CTsurgery https://t.co/GHrYn5I5WO pic.twitter.com/Y0mKC0zONu
— SCAI Now (@SCAI) January 31, 2022
The Lancet Commission: Experts warn of the increasing overmedicalization of death, call for radical rethink of how society cares for dying people.
1 Feb, 2022 | 09:55h | UTCHomepage: Lancet Commission on the Value of Death (free registration required for all articles)
Report of the Lancet Commission on the Value of Death: bringing death back into life
The precariousness of balancing life and death
Ros Taylor: seeing palliative care as relational
Commentary on Twitter (thread – click for more)
Increasing overmedicalisation at the end of life is denying people & their families a good death.
Towards a compassionate community model: The Lancet #ValueofDeath Commission calls for a radical rethink of care for the dying & attitudes to death. https://t.co/DpJiu1tOcV pic.twitter.com/FU9MgCO1J6
— The Lancet (@TheLancet) January 31, 2022
Observational study: Pharmacist involvement in the care of critically ill patients may reduce resource utilization, adverse drug events, and medical costs.
1 Feb, 2022 | 09:47h | UTC
Commentary from the author on Twitter (thread – click for more)
PHARM-CRIT Study
?? 215 ICU PharmDs at 85 centers
?55,926 accepted interventions on 27,681 patients over 3,148 shifts
?$23,404,089 cost avoidance; monetary benefit-to-cost ratio for ICU pharmacists $3.3:1 – $9.6:1@SCCM_CPP @SCCM #TwitteRx #PharmICU https://t.co/Hv4jPwU6eb— Megan Rech, PharmD, MS (@MeganARech) December 16, 2021
RCT: Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant.
1 Feb, 2022 | 08:58h | UTCCommentaries:
Normothermic Machine Perfusion Improves Outcomes in Liver Transplant Recipients – Physician’s Weekly
Machine Perfusion Cuts Early Graft Dysfunction in Liver Transplantation – MedPage Today (free registration required)
Related:
RCT: Hypothermic machine perfusion in liver transplantation
Transplantation of Discarded Livers Following Viability Testing with Normothermic Machine Perfusion
Commentaries on Twitter
Study found portable normothermic oxygenated machine perfusion of donor liver grafts resulted in improved outcomes of liver transplantation and in more livers being transplanted. https://t.co/PZzvFriJvB pic.twitter.com/2icSfxoLDF
— JAMA Surgery (@JAMASurgery) January 5, 2022
Study found portable normothermic oxygenated machine perfusion of donor liver grafts resulted in improved outcomes of liver transplantation and in more livers being transplanted. https://t.co/TKEsTf8Htu pic.twitter.com/tg2xDGDyOS
— JAMA Surgery (@JAMASurgery) January 5, 2022
[Preprint] Study suggests SARS-CoV-2 Omicron subvariants BA.2 is even more transmissible than the original variant.
1 Feb, 2022 | 08:56h | UTCCommentaries:
Study suggests BA.2 COVID-19 subvariant more contagious – CIDRAP
‘Stealth Omicron’ spreads more than original strain: study – MedicalXpress
Commentary from the author on Twitter (thread – click for more)
New Preprint Out!
“Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households”
We investigate the secondary attack rate (SAR) in #Omicron BA.1 vs. BA.2 households in Demark, 20 December 2021 – 18 January 2022.https://t.co/F3XBH2LnW9
1/ pic.twitter.com/MwGPNYkOg8— Frederik Plesner Lyngse (@LyngseF) January 31, 2022
Does the world need an Omicron vaccine? What researchers say.
1 Feb, 2022 | 08:53h | UTCDoes the world need an Omicron vaccine? What researchers say – Nature
Consensus: Nephrotoxins and acute kidney injury.
1 Feb, 2022 | 08:46h | UTC
Will Omicron end the pandemic? Here’s what experts say.
1 Feb, 2022 | 08:54h | UTCWill Omicron end the pandemic? Here’s what experts say – Nature
Randomized trials on non-pharmaceutical interventions for COVID-19 as of August 2021: a scoping review.
1 Feb, 2022 | 08:51h | UTCRelated:
Study ranks the most effective non-pharmaceutical interventions for reducing COVID-19 spread
Effect of Non-pharmaceutical Interventions to Contain COVID-19 in China
Commentary from the author on Twitter (thread – click for more)
Our analysis of trials on NPIs for COVID-19 just published with the wonderful Julian Hirt & @PerrineJaniaud ! @BMJ_EBM @CovidEvidence https://t.co/4AIaATl4Jk
1/4 pic.twitter.com/jbd9FIF299
— Lars G. Hemkens (@LGHemkens) January 28, 2022
M-A: Vasopressin and glucocorticoids for in-hospital cardiac arrest.
1 Feb, 2022 | 08:43h | UTC
Commentary on Twitter
Systemic review and meta analysis post VAM-IHCA.
▶️ Moderate certainty for benefit with steroids and vasopressin on ROSC
▶️ Less certainty for longer term outcomes @mathiasholmb@LarsWAndersen1 @AsgerGranfeldthttps://t.co/K3jZ1gBs1h— Critical Care Reviews (@CritCareReviews) January 4, 2022
The extraordinary success of Covid-19 vaccines, in two charts.
1 Feb, 2022 | 08:48h | UTCThe extraordinary success of Covid-19 vaccines, in two charts – Vox
Systematic Review: Change in resting heart rate and risk for all-cause mortality.
1 Feb, 2022 | 08:40h | UTC
Commentary on Twitter
What's the resting heart rate? How does it change? To keep in mind: there may be a correlation w all-cause mortality. Check the #EJPC paper of the week by @WDerman @m_heine01 et al. https://t.co/fCq0NxIx4v#CVPrev #EAPC_ESC #heart @m_piepoli @SilCastelletti @paolo_emilio pic.twitter.com/xJn2nbmPLS
— European Society of Cardiology Journals (@ESC_Journals) January 30, 2022
Observational Study: Same-day mastectomy and axillary lymph node dissection seems safe for most patients with breast cancer.
1 Feb, 2022 | 08:38h | UTC
Recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis.
1 Feb, 2022 | 08:44h | UTC
Research methods & reporting: Incorporating dose effects in network meta-analysis.
1 Feb, 2022 | 08:39h | UTCIncorporating dose effects in network meta-analysis – The BMJ
See also: thread from the author on Twitter summarizing the article
RCT: In patients with rheumatoid arthritis, treatment with oral drug Tofacitinib increases cardiovascular and cancer risk compared to treatment with subcutaneous TNF inhibitors.
1 Feb, 2022 | 08:35h | UTCCardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)
Video: CV and Cancer Risk with Tofacitinib in RA – New England Journal of Medicine
Commentary: CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis – HealthDay
RCT: A comprehensive geriatric assessment hospital at home may be a cost-effective alternative to hospital admission.
1 Feb, 2022 | 08:32h | UTC
Review | Hepatic encephalopathy: thinking beyond ammonia.
1 Feb, 2022 | 08:36h | UTCHepatic Encephalopathy: Thinking Beyond Ammonia – Clinical Liver Disease
Concussion management is changing as more research suggests exercise is the best approach.
1 Feb, 2022 | 08:27h | UTCRelated:
Guideline: Nonpharmacological treatment of persistent postconcussion symptoms in adults.
Randomized Trial: Early Aerobic Exercise for Sport-Related Concussion
RCT: Limiting screen time for young adults after concussion results in shorter duration of symptoms.
RCT: Early drain removal is safe in patients with low or intermediate risk of pancreatic fistula after pancreaticoduodenectomy.
1 Feb, 2022 | 08:33h | UTCEarly Drain Removal is Safe in Patients With Low or Intermediate Risk of Pancreatic Fistula After Pancreaticoduodenectomy: A Multicenter, Randomized Controlled Trial – Annals of Surgery (link to abstract – $ for full-text)
Review: Primary care-based cardiovascular disease risk management after adverse pregnancy outcomes.
1 Feb, 2022 | 08:29h | UTCPrimary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine (if the link is paywalled, try this one)
See also: thread from the author on Twitter summarizing the article
Related:
AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk
Cohort Study: Preeclampsia and Cardiovascular Disease
Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors (recent studies on the subject)
Systematic Review: Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases.
1 Feb, 2022 | 08:20h | UTC
Commentary on Twitter
What is the added value of #imaging in interventional procedures in musculoskeletal diseases?
Check out our recent systematic literature review informing EULAR points to consider
✅needle positioning
? heterogeneity and risk of bias? https://t.co/qdcNuKECxH@pedrommcmachado
— ARD & RMD Open (@ARD_BMJ) December 9, 2021
RCT: Sugemalimab improves progression-free survival vs. placebo in patients with metastatic non-small-cell lung cancer.
1 Feb, 2022 | 08:25h | UTCSugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link to abstract – $ for full-text)
Related study: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters
Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (free registration required)
Commentary on Twitter
In the phase III GEMSTONE-302 trial of chemo + sugemalimab or placebo in 479 with untreated advanced-stage NSCLC, mPFS was 9.0 vs 4.9 months (HR 0.48; P<0.0001); OS was 72.4% vs 62.0% at 12 months & 47.1% vs 38.1% at 24 months (HR 0.67, 95% CI 0.50–0.90): https://t.co/z6f00tqy8B
— NatureRevClinOncol (@NatRevClinOncol) January 19, 2022
Meta-analysis: Androgen deprivation therapy, in addition to radiotherapy, is associated with improved metastasis-free survival in men with localized prostate cancer.
1 Feb, 2022 | 08:24h | UTCAndrogen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)